Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,198 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control/Placebo group Clear all
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915
View directory record Official record
Conditions
Generalized Tonic Clonic Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome

NCT03182725
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
Ivabradine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 11, 2026, 4:57 PM EDT
Withdrawn Phase 2 Interventional

Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent

NCT02689713
View directory record Official record
Conditions
Pain, Thermal Injury, Burns, Hyperalgesia
Interventions
Voriconazole (topical), Topical Sterile Water Placebo Group
Drug
Lead sponsor
Kenneth Hargreaves
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

NCT03030248
View directory record Official record
Conditions
Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lubiprostone, Colonic Motility and Sensation

NCT00953043
View directory record Official record
Conditions
Healthy
Interventions
lubiprostone, Placebo, Bowel preparation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 11, 2026, 4:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Neuroimaging Study of Open-label Placebo in Depressed Adolescents

NCT04201106
View directory record Official record
Conditions
Depression
Interventions
Open Label Placebo with Rationale, Open Label Placebo without Rationale
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia

NCT01898884
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
VP 20629, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT 60 µg, RSV MAT 120 µg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 11, 2026, 4:57 PM EDT
Active, not recruiting Not applicable Interventional

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

NCT06670040
View directory record Official record
Conditions
ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder, MDD
Interventions
Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 26 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 11, 2026, 4:57 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

NCT05267535
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Piromelatine 20 mg, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
60 Years to 85 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
32
States / cities
Costa Mesa, California • Long Beach, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT00041717
View directory record Official record
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 11, 2026, 4:57 PM EDT
Not yet recruiting Phase 2 Interventional

Single-dose Prophylactic INdomethacin in Extremely Preterm Infants

NCT06572917
View directory record Official record
Conditions
Extreme Prematurity, Intraventricular Hemorrhage, Morbidity;Newborn
Interventions
Indomethacin, Placebo
Drug
Lead sponsor
University of British Columbia
Other
Eligibility
0 Hours to 12 Hours
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Roseville, California • Sacramento, California • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

NCT00040443
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
CX516, Placebo
Drug
Lead sponsor
RespireRx
Industry
Eligibility
55 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Peoria, Arizona • Irvine, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

NCT02031640
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate, Placebo, Albuterol/salbutamol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
94
States / cities
Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

NCT01236040
View directory record Official record
Conditions
Influenza
Interventions
GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A, GSK Biologicals' investigational vaccine GSK2340273A, Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

NCT04444050
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986331, Placebo, Matching BMS-986331
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 11, 2026, 4:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774
View directory record Official record
Conditions
Spasticity
Interventions
Corabotase, Placebo, Dysport
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Downey, California • Overland Park, Kansas • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 4 Interventional Results available

Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression

NCT00607789
View directory record Official record
Conditions
Binge Eating, Depression
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 11, 2026, 4:57 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

NCT03743649
View directory record Official record
Conditions
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Terminated Phase 3 Interventional

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

NCT00325650
View directory record Official record
Conditions
Prediabetic State
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
2,420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 11, 2026, 4:57 PM EDT
Recruiting Not applicable Interventional

Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

NCT06184126
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Acute Pain
Interventions
Virtual Reality Headset and Hand-Held Controllers, Blindfolding and Noise Cancelling
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 11, 2026, 4:57 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DZP, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
16 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
62
States / cities
Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 11, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event

NCT01578629
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack (TIA)
Interventions
Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin, Placebo vehicle control
Other
Lead sponsor
Andrew Slivka
Other
Eligibility
40 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 11, 2026, 4:57 PM EDT